Enliven Therapeutics Inc Stock Price, News & Analysis

Enliven Therapeutics (Nasdaq: ELVN) announced Rick Fair as Chief Executive Officer and board member, effective December 11, 2025, while co-founder Sam Kintz moves to Head of Pipeline. The leadership change is positioned to support a planned pivotal Phase 3 trial of ELVN-001 in chronic myeloid leukemia (CML), targeted to start in 2026, and future commercialization.

Mr. Fair brings 25+ years of product development and commercialization experience, including leadership roles at Bellicum, Roche/Genentech and Johnson & Johnson, and oversight of launches and commercialization planning for a $23 billion portfolio. Sam Kintz will focus on advancing early pipeline assets toward the clinic.

Enliven Therapeutics (Nasdaq: ELVN) reported Q3 2025 results and a clinical update on ELVN-001 in chronic myeloid leukemia (CML). The company completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial (NCT05304377) and remains on track to initiate a Phase 3 pivotal trial in 2026. Cash, cash equivalents and marketable securities were $477.6 million as of September 30, 2025, which management expects will fund operations into the first half of 2029.

Q3 operating items: R&D $18.2M, G&A $6.9M, and net loss $20.1M.

Enliven Therapeutics (Nasdaq: ELVN) reported Q3 2025 results and a clinical update on Nov 12, 2025. Key highlights: completed dosing in the randomized Phase 1b cohorts of the ENABLE trial for ELVN-001 in CML and remains on track to initiate a global Phase 3 pivotal trial in 2026. Management presented ENABLE data at multiple international meetings and will present additional subset data at ASH 2025 on Dec 7, 2025. Financials: cash, cash equivalents and marketable securities of $477.6M, expected to provide runway into the first half of 2029. Q3 operating figures: R&D $18.2M, G&A $6.9M, net loss $20.1M.

Enliven Therapeutics (Nasdaq: ELVN) will present preliminary Phase 1a/1b ENABLE data on ELVN-001 in chronic myeloid leukemia patients with atypical BCR::ABL1 fusion transcripts at ASH 2025 (Dec 6-9).

As of Apr 28, 2025 six previously treated chronic phase CML patients with atypical transcripts received ELVN-001 (20–80 mg BID; some escalated to 120 mg QD). Four patients were efficacy-evaluable and showed transcript reductions including multiple >1 log decreases, a fall from 0.95% to 0.15%, and durable on-study durations (80–505 days). No treatment-emergent adverse events >Grade 2 were reported in these patients. Presentation details: poster session Dec 7, 6:00–8:00 p.m. ET.

Enliven Therapeutics (Nasdaq: ELVN) announced upcoming presentations of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia.

The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress.

Enliven Therapeutics (Nasdaq: ELVN) reported significant progress in Q2 2025, highlighted by positive Phase 1 clinical trial results for ELVN-001 in chronic myeloid leukemia (CML) treatment. The trial demonstrated a 47% cumulative MMR rate, with 32% of patients achieving MMR by 24 weeks, surpassing historical data from competitor treatments.

The company strengthened its financial position through a $230 million public offering, ending Q2 with $490.5 million in cash and equivalents, extending runway into H1 2029. Quarterly financials showed R&D expenses of $21.5 million and a net loss of $25.3 million. Enliven plans to initiate a Phase 3 pivotal trial in 2026.

Enliven Therapeutics (Nasdaq: ELVN) has successfully closed its public offering, raising approximately $230 million in gross proceeds. The offering included 9,920,987 shares of common stock at $19.66 per share, including the full exercise of the underwriters' option for 1,526,250 additional shares. Additionally, the company issued pre-funded warrants to purchase 1,780,263 shares at $19.659 per warrant. The offering was managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho as joint book-running managers, with LifeSci Capital acting as lead manager. The securities were offered through a Registration Statement on Form S-3 and related filings with the SEC.

Enliven Therapeutics (ELVN) has announced the pricing of its public offering, consisting of 8,394,737 shares of common stock at $19.66 per share and pre-funded warrants for up to 1,780,263 shares at $19.659 per warrant. The gross proceeds are expected to be approximately $200 million before deducting expenses. The offering is set to close around June 16, 2025. The company has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in common stock. The offering is being managed by joint book-runners Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital as lead manager. The offering will be made through a Registration Statement on Form S-3 and is subject to market conditions and regulatory approval.